Arexvy could help NHS deal with virus that causes about 8,000 deaths among older people in UK each year
The UK’s medicines regulator has approved the first vaccine against respiratory syncytial virus (RSV) in older adults.
The virus typically causes cold-like symptoms, but is a leading cause of pneumonia in infants and elderly people, with infections in older adults accounting for about 8,000 deaths, 14,000 hospitalisations and 175,000 GP appointments in the UK each year – more than influenza during a typical winter season.
About Author
More Stories
‘Wild west’: experts concerned by illegal promotion of weight-loss jabs in UK
Esports are booming in Africa – but can its infrastructure keep pace?
Shrinking waistlines and growing profits: the weight-loss drug boom